Could cause temporary or reversible harm; serious harm is unlikely.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.
| Brand name | VALSARTAN |
| Generic name | VALSARTAN |
| Active ingredient(s) | VALSARTAN |
| Distributed by / for | Aurobindo Pharma USA, Inc., Dayton, NJ --- |
| NDC | 65862-571-90 |
| Full product label | Valsartan Tablets USP 80 mg, 90 count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., Dayton, NJ --- NDC 65862-571-90 |
| Recalling firm | Aurobindo Pharma USA Inc. |
| Distribution | Product was distributed to major distribution chains throughout the United States. |
| Quantity | N/A |
| Recall initiated | 2018-12-31 |
| Report date | 2019-03-27 |
| Recall completed | — |
| Recall number | D-1038-2019 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | East Windsor NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗